Aaron Goodman

Title(s)Associate Clinical Professor, Medicine
SchoolVc-health Sciences-schools
Address9500 Gilman Drive #
La Jolla CA 92093
vCardDownload vCard

    Collapse Overview 

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Daratumumab and missed sequencing opportunities in transplant-ineligible multiple myeloma: lessons for future trials. Nat Rev Clin Oncol. 2025 May 29. Mohyuddin GR, Goodman AM. PMID: 40442311.
      View in: PubMed   Mentions:
    2. Prevalence of medical writing in hematological malignancy review articles. BMC Cancer. 2025 Apr 17; 25(1):720. Vaquera-Alfaro HA, Nasrollahi E, Mangala YO, Russler-Germain D, Goodman A, Mohyuddin GR. PMID: 40247240; PMCID: PMC12007303.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    3. Evaluating early intervention in smoldering myeloma clinical trials: a systematic review. Oncologist. 2025 Feb 06; 30(2). Kakkilaya A, Trando A, Cliff ERS, Mian H, Al Hadidi S, Aziz M, Goodman AM, Jeong AR, Smith WL, Kelkar AH, Russler-Germain DA, Mehra N, Chakraborty R, Gertz MA, Mohyuddin GR. PMID: 39236068; PMCID: PMC11883161.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    4. Common Sense Oncology principles for the design, analysis, and reporting of phase 3 randomised clinical trials. Lancet Oncol. 2025 Feb; 26(2):e80-e89. Gyawali B, Eisenhauer EA, van der Graaf W, Booth CM, Cherny NI, Goodman AM, Koven R, Pe ML, Marini BL, Mohyuddin GR, Pond GR, Sengar M, Soto-Perez-de-Celis E, Trapani D, Tregear M, Wilson BE, Tannock IF. PMID: 39914429.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    5. The lifecycle and evolution of new regimens on the National Comprehensive Cancer Network Guidelines for newly diagnosed multiple myeloma. Oncologist. 2024 Dec 24. Mohyuddin GR, Almasri J, Goodman A, Haslam A, Prasad V. PMID: 39719103.
      View in: PubMed   Mentions:    Fields:    
    6. Higher tumor mutational burden and PD-L1 expression correlate with shorter survival in hematologic malignancies. Ther Adv Med Oncol. 2024; 16:17588359241273053. Jeong AR, Trando AH, Thomas SD, Riviere P, Sakowski PJ, Sokol ES, Goodman AM, Kurzrock R. PMID: 39220298; PMCID: PMC11363031.
      View in: PubMed   Mentions: 2  
    7. Radiation-associated cutaneous mastocytosis: a case report and review of the literature. Acta Oncol. 2024 Aug 14; 63:685-688. Austin KM, Hinds B, Jeong AR, Goodman AM. PMID: 39143718; PMCID: PMC11340647.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    8. Overtreatment of multiple myeloma and its precursor states: de-escalation is an urgent need in clinical practice and trials. Nat Rev Clin Oncol. 2024 Aug; 21(8):561-562. Mohyuddin GR, Goodman AM. PMID: 38649423.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    9. The CNS relapse in T-cell lymphoma index predicts CNS relapse in patients with T- and NK-cell lymphomas. Blood Adv. 2024 07 09; 8(13):3507-3518. Bhansali RS, Ellin F, Relander T, Cao M, Li W, Long Q, Ganesan N, Stuver R, Horwitz SM, Wudhikarn K, Hwang SR, Bennani NN, Chavez J, Sokol L, Saeed H, Duan F, Porcu P, Pullarkat P, Mehta-Shah N, Zain JM, Ruiz M, Brammer JE, Prakash R, Iyer SP, Olszewski AJ, Major A, Riedell PA, Smith SM, Goldin C, Haverkos B, Hu B, Zhuang TZ, Allen PB, Toama W, Janakiram M, Brooks TR, Jagadeesh D, Hariharan N, Goodman AM, Hartman G, Ghione P, Fayyaz F, Rhodes JM, Chong EA, Gerson JN, Landsburg DJ, Nasta SD, Schuster SJ, Svoboda J, Jerkeman M, Barta SK. PMID: 38739715; PMCID: PMC11261035.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    10. Dietary interventions in cancer: a systematic review of all randomized controlled trials. J Natl Cancer Inst. 2024 Jul 01; 116(7):1026-1034. Ilerhunmwuwa NP, Abdul Khader AHS, Smith C, Cliff ERS, Booth CM, Hottel E, Aziz M, Lee-Smith W, Goodman A, Chakraborty R, Mohyuddin GR. PMID: 38429997; PMCID: PMC11223872.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    11. Use of subjective minimizing language at hematology and oncology conferences: A systematic review. J Cancer Policy. 2024 Mar; 39:100461. Abusamak AA, Abusamak M, Al-Abbadi M, Rayyan A, Oran O, Mohyuddin GR, Kelkar AH, Goodman AM, Chakraborty R, Cliff ERS, Al Hadidi S. PMID: 38061494.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    12. Adverse Event Reporting in Randomized Clinical Trials for Multiple Myeloma. JAMA Netw Open. 2023 11 01; 6(11):e2342195. Najjar M, McCarron J, Cliff ERS, Berger K, Steensma DP, Al Hadidi S, Chakraborty R, Goodman A, Anto E, Greene T, Sborov D, Mohyuddin GR. PMID: 37948080; PMCID: PMC10638643.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    13. Characteristics of post hoc subgroup analyses of oncology clinical trials: a systematic review. JNCI Cancer Spectr. 2023 10 31; 7(6). Alrawabdeh J, Alzu'bi M, Alzyoud M, Odeh N, Hamadneh Y, Mian H, Mohyuddin GR, Kelkar AH, Goodman AM, Chakraborty R, Russler-Germain DA, Mehra N, Baggio D, Cliff ERS, Al Hadidi S. PMID: 38006333; PMCID: PMC11025370.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    14. Common Sense Oncology: including everyone - Authors' reply. Lancet Oncol. 2023 10; 24(10):e404. Booth CM, Sengar M, Goodman A, Wilson B, Gyawali B. PMID: 37797642.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    15. Outcomes of Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Large B-Cell Lymphoma (LBCL): A Single-Institution Experience. Cancers (Basel). 2023 Sep 21; 15(18). Trando A, Ter-Zakarian A, Yeung P, Goodman AM, Hamdan A, Hurley M, Jeong AR, Tzachanis D. PMID: 37760639; PMCID: PMC10527363.
      View in: PubMed   Mentions: 3  
    16. #MedEd: Medical Education and Knowledge Translation on Social Media. JAMA. 2023 09 12; 330(10):909-910. Ayers JW, Goodman AM, Smith DM. PMID: 37642959; PMCID: PMC10792539.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    17. Successful treatment of non-Langerhans cell histiocytosis with the MEK inhibitor trametinib: a multicenter analysis. Blood Adv. 2023 08 08; 7(15):3984-3992. Aaroe A, Kurzrock R, Goyal G, Goodman AM, Patel H, Ruan G, Ulaner G, Young J, Li Z, Dustin D, Go RS, Diamond EL, Janku F. PMID: 36857436; PMCID: PMC10410131.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    18. Common Sense Oncology: outcomes that matter. Lancet Oncol. 2023 08; 24(8):833-835. Booth CM, Sengar M, Goodman A, Wilson B, Aggarwal A, Berry S, Collingridge D, Denburg A, Eisenhauer EA, Ginsburg O, Goldstein D, Gunasekera S, Hammad N, Honda K, Jackson C, Karikios D, Knopf K, Koven R, Marini BL, Maskens D, Moraes FY, Mohyuddin GR, Poudyal BS, Pramesh CS, Roitberg F, Rubagumya F, Schott S, Sirohi B, Soto-Perez-de-Celis E, Sullivan R, Tannock IF, Trapani D, Tregear M, van der Graaf W, Vanderpuye V, Gyawali B. PMID: 37467768.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    19. The essential role of randomised controlled trials. Lancet Haematol. 2023 07; 10(7):e486-e487. Marini BL, Goodman AM, Perissinotti AJ. PMID: 37407137.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    20. Attrition and withdrawal in multiple myeloma randomized controlled trials: A systematic review. Eur J Haematol. 2023 Sep; 111(3):491-498. Hentzen S, Meirson T, Koehn K, Goodman A, Chakraborty R, Sborov D, Rubinstein S, Mohyuddin GR. PMID: 37382045.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    21. First use of ibrutinib for the treatment of post-transplant central nervous system graft-versus-host disease. Br J Haematol. 2023 09; 202(5):1061-1064. Trando A, Dunn-Pirio A, Koura D, Goodman AM. PMID: 37357559.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    22. Randomised controlled trials evaluating anticancer therapies in haematological cancers: an overview of global research activity. Ecancermedicalscience. 2023; 17:1558. Sengar M, Hopman WM, Mohyuddin GR, Goodman AM, Gyawali B, Mukherji D, Hammad N, Pramesh CS, Aggarwal A, Sullivan R, Booth CM. PMID: 37396096; PMCID: PMC10310333.
      View in: PubMed   Mentions:
    23. Comparing Physician and Artificial Intelligence Chatbot Responses to Patient Questions Posted to a Public Social Media Forum. JAMA Intern Med. 2023 06 01; 183(6):589-596. Ayers JW, Poliak A, Dredze M, Leas EC, Zhu Z, Kelley JB, Faix DJ, Goodman AM, Longhurst CA, Hogarth M, Smith DM. PMID: 37115527; PMCID: PMC10148230.
      View in: PubMed   Mentions: 466     Fields:    Translation:Humans
    24. Autoimmune HLA Alleles and Neoepitope Presentation Predict Post-Allogenic Transplant Relapse. J Immunother Precis Oncol. 2023 Aug; 6(3):127-132. Castro A, Goodman AM, Rane Z, Talwar JV, Frampton GM, Morris GP, Lippman SM, Zhang X, Kurzrock R, Carter H. PMID: 37637234; PMCID: PMC10448732.
      View in: PubMed   Mentions:
    25. The Landscape of Currently Enrolling Maintenance Trials in Multiple Myeloma. Clin Hematol Int. 2023 Jun; 5(2-3):170-176. Tariq SM, Abdallah AO, Goodman A, Sborov D, Mohyuddin GR, Britt A. PMID: 37133718; PMCID: PMC10241733.
      View in: PubMed   Mentions: 2  
    26. Ineligible for transplant, but eligible for intensive quadruplet therapy-The value of 'add-on' trials for vulnerable patient populations. Eur J Cancer. 2023 May; 185:164-166. Mohyuddin GR, Goodman AM. PMID: 36996626.
      View in: PubMed   Mentions:    Fields:    
    27. Quality of content reporting on two major oncology media websites: OncLive and Targeted Oncology. J Cancer Policy. 2023 06; 36:100411. Sharma N, Wayant C, Neupane K, Lenka J, Berger K, Goodman AM, Booth CM, Prasad V, Mohyuddin GR. PMID: 36773798.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    28. Analysis of repeated roles in editorial boards at oncology focused journals. J Cancer Policy. 2023 03; 35:100380. Sawalha L, Kelkar AH, Mohyuddin GR, Goodman AM, Gagelmann N, Al Hadidi S. PMID: 36538988.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    29. Time-to-event surrogate end-points in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysis. Br J Haematol. 2023 03; 200(5):587-594. Etekal T, Koehn K, Sborov DW, McClune B, Prasad V, Haslam A, Berger K, Booth C, Al Hadidi S, Abdallah AO, Goodman A, Mohyuddin GR. PMID: 36495317.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    30. Characteristics of measurable residual disease assessment in myeloma: a review of clinical trials from 2015-2020. Blood Cancer J. 2022 11 15; 12(11):155. Van Oekelen O, Birrer N, Wesson W, Galate VL, Cliff ERS, Goodman AM, Abdallah AO, Chakraborty R, Prasad V, Mohyuddin GR. PMID: 36379917; PMCID: PMC9666639.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    31. Tumor Infiltrating Lymphocyte Expression of PD-1 Predicts Response to Anti-PD-1/PD-L1 Immunotherapy. J Immunother Precis Oncol. 2022 Nov; 5(4):90-97. Bevins NJ, Okamura R, Montesion M, Adashek JJ, Goodman AM, Kurzrock R. PMID: 36483582; PMCID: PMC9714418.
      View in: PubMed   Mentions: 15  
    32. Ivosidenib and Azacitidine in IDH1-Mutated AML. N Engl J Med. 2022 06 30; 386(26):2536. Goodman AM, Mohyuddin GR, Prasad V. PMID: 35767449.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    33. Outcomes of Autologous Hematopoietic Cell Transplantation in Older Patients with Diffuse Large B-Cell Lymphoma. Transplant Cell Ther. 2022 08; 28(8):487.e1-487.e7. Munshi PN, Chen Y, Ahn KW, Awan FT, Cashen A, Shouse G, Shadman M, Shaughnessy P, Zurko J, Locke FL, Goodman AM, Bisneto JCV, Sauter C, Kharfan-Dabaja MA, Meyers G, Jaglowski S, Herrera A, Hamadani M. PMID: 35609865; PMCID: PMC9375438.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    34. Age-Adjusted Schedules of Venetoclax and Hypomethylating Agents to Treat Extremely Elderly Patients with Acute Myeloid Leukemia. Case Rep Hematol. 2022; 2022:2802680. Lee AM, Goodman AM, Mangan JK. PMID: 35515507; PMCID: PMC9064535.
      View in: PubMed   Mentions: 1  
    35. Effects of financial toxicity on prescription drug use and mental well-being in cancer patients. Explor Res Clin Soc Pharm. 2022 Jun; 6:100136. Chan K, Sepassi A, Saunders IM, Goodman A, Watanabe JH. PMID: 35909716; PMCID: PMC9335927.
      View in: PubMed   Mentions: 2  
    36. T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022 03; 20(3):285-308. Horwitz SM, Ansell S, Ai WZ, Barnes J, Barta SK, Brammer J, Clemens MW, Dogan A, Foss F, Ghione P, Goodman AM, Guitart J, Halwani A, Haverkos BM, Hoppe RT, Jacobsen E, Jagadeesh D, Jones A, Kallam A, Kim YH, Kumar K, Mehta-Shah N, Olsen EA, Rajguru SA, Rozati S, Said J, Shaver A, Shea L, Shinohara MM, Sokol L, Torres-Cabala C, Wilcox R, Wu P, Zain J, Dwyer M, Sundar H. PMID: 35276674.
      View in: PubMed   Mentions: 69     Fields:    Translation:Humans
    37. Post-protocol therapy and informative censoring in the CANDOR study. Lancet Oncol. 2022 03; 23(3):e97. Meirson T, Markel G, Prasad V, Goodman AM, Mohyuddin GR. PMID: 35240098.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    38. Heterogeneity of enrolment criteria for ongoing smouldering myeloma trials. Br J Haematol. 2022 06; 197(6):e86-e88. Soomro MA, Hoffman J, Goodman AM, Sborov DW, Mohyuddin GR. PMID: 35229286.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    39. Characteristics of clinical trials for haematological malignancies from 2015 to 2020: A systematic review. Eur J Cancer. 2022 05; 167:152-160. Wesson W, Galate VL, Sborov DW, McClune B, Goodman AM, Gyawali B, Prasad V, Abbasi S, Mohyuddin GR. PMID: 35236569.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    40. Characterisation of infections in patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent. Br J Haematol. 2022 04; 197(1):63-70. On S, Rath CG, Lan M, Wu B, Lau KM, Cheung E, Alegria W, Young R, Tan M, Kim C, Phun J, Patel N, Mannis G, Logan AC, Kennedy V, Goodman A, Taplitz RA, Young PA, Wen R, Saunders IM. PMID: 35174480.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    41. Synthetic control arms in studies of multiple myeloma and diffuse large B-cell lymphoma. Br J Haematol. 2022 03; 196(5):1274-1277. Banerjee R, Midha S, Kelkar AH, Goodman A, Prasad V, Mohyuddin GR. PMID: 34750805.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    42. Practicing on the edge of oncology: when standard of care feels uncomfortable. Nat Rev Clin Oncol. 2021 11; 18(11):673-674. Booth CM, Goodman AM. PMID: 34385680.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    43. Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021 11; 19(11):1277-1303. Go RS, Jacobsen E, Baiocchi R, Buhtoiarov I, Butler EB, Campbell PK, Coulter DW, Diamond E, Flagg A, Goodman AM, Goyal G, Gratzinger D, Hendrie PC, Higman M, Hogarty MD, Janku F, Karmali R, Morgan D, Raldow AC, Stefanovic A, Tantravahi SK, Walkovich K, Zhang L, Bergman MA, Darlow SD. PMID: 34781268.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    44. Perils of Ignoring Overall Survival in Interpreting the Myeloma Literature. J Clin Oncol. 2022 01 01; 40(1):105-106. Mohyuddin GR, Goodman AM, Knopf K. PMID: 34652953.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    45. Assessing CAR T-Cell Therapy Response Using Genome-Wide Sequencing of Cell-Free DNA in Patients With B-Cell Lymphomas. Transplant Cell Ther. 2022 01; 28(1):30.e1-30.e7. Goodman AM, Holden KA, Jeong AR, Kim L, Fitzgerald KD, Almasri E, McLennan G, Eisenberg M, Jahromi AH, Hoh C, Hurley M, Mulroney C, Tzachanis D, Ball ED, Jensen TJ, Kurzrock R. PMID: 34655803.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    46. Intra-patient stability of tumor mutational burden from tissue biopsies at different time points in advanced cancers. Genome Med. 2021 10 12; 13(1):159. Pham TV, Goodman AM, Sivakumar S, Frampton G, Kurzrock R. PMID: 34641956; PMCID: PMC8513181.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    47. Novel somatic alterations in unicentric and idiopathic multicentric Castleman disease. Eur J Haematol. 2021 Dec; 107(6):642-649. Goodman AM, Jeong AR, Phillips A, Wang HY, Sokol ES, Cohen PR, Sicklick J, Fajgenbaum DC, Kurzrock R. PMID: 34431136; PMCID: PMC9624446.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    48. Lack of equipoise in the LIGHTHOUSE trial for patients with relapsed multiple myeloma: An ethical concern. Eur J Cancer. 2021 11; 157:533-535. Mohyuddin GR, Banerjee R, Goodman AM. PMID: 34544634.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    49. FMS-Like Tyrosine Kinase 3 Inhibitors for the Treatment of Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2022 03; 22(3):e161-e184. Novatcheva ED, Anouty Y, Saunders I, Mangan JK, Goodman AM. PMID: 34649791.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    50. Genome-wide Sequencing of Cell-free DNA Enables Detection of Copy-number Alterations in Patients with Cancer Where Tissue Biopsy is Not Feasible. Mol Cancer Ther. 2021 11; 20(11):2274-2279. Jensen TJ, Goodman AM, Ellison CK, Holden KA, Kato S, Kim L, Daniels GA, Fitzgerald K, McCarthy E, Nakashe P, Mazloom AR, Almasri E, McLennan G, Grosu DS, Eisenberg M, Kurzrock R. PMID: 34465593; PMCID: PMC9398131.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    51. Intention to treat versus modified intention-to-treat analysis in B-cell maturation antigen and CD19 chimeric antigen receptor trials: A systematic review and meta-analysis. Eur J Cancer. 2021 10; 156:164-174. Mohyuddin GR, Atieh T, Ahmed N, Sborov D, McClune B, Abdallah AO, Goodman AM, Aziz M, Allen I, Prasad V. PMID: 34454318.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    52. The landscape of trials for smoldering multiple myeloma: endpoints, trial design, and lessons learnt. Leuk Lymphoma. 2021 11; 62(11):2793-2795. Mohyuddin GR, Ouchveridze E, Goodman A, Prasad V. PMID: 34114943.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    53. Multiple myeloma triplet therapies: baseline characteristics and control groups. Lancet. 2021 05 01; 397(10285):1620-1621. Mohyuddin GR, Abdallah AO, McClune B, Goodman A, Prasad V. PMID: 33933200.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    54. Rosai-Dorfman-Destombes (RDD) disease presenting as palindromic rheumatism. BMC Med Imaging. 2021 04 15; 21(1):72. Haghighat Jahromi A, Goodman AM, Hoh CK. PMID: 33858362; PMCID: PMC8050901.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    55. Reporting of Postprotocol Therapies and Attrition in Multiple Myeloma Randomized Clinical Trials: A Systematic Review. JAMA Netw Open. 2021 04 01; 4(4):e218084. Mohyuddin GR, Koehn K, Abdallah AO, Goodman AM, Prasad V. PMID: 33909053; PMCID: PMC8082314.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    56. Quality of control groups in randomised trials of multiple myeloma enrolling in the USA: a systematic review. Lancet Haematol. 2021 Apr; 8(4):e299-e304. Mohyuddin GR, Koehn K, Sborov D, McClune B, Abdallah AO, Goodman AM, Prasad V. PMID: 33770485.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    57. STK11 alterations in the pan-cancer setting: prognostic and therapeutic implications. Eur J Cancer. 2021 05; 148:215-229. Krishnamurthy N, Goodman AM, Barkauskas DA, Kurzrock R. PMID: 33744718; PMCID: PMC10344467.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    58. Case Report: Multiple Chromosomal Translocations Including Novel CIITA-CREBBP Fusion and Mutations in a Follicular Lymphoma. Front Oncol. 2021; 11:620435. Wang HY, Sokol ES, Goodman AM, Feldman AL, Mulroney CM. PMID: 33777766; PMCID: PMC7988195.
      View in: PubMed   Mentions: 1  
    59. Persistent challenges with treating multiple myeloma early. Blood. 2021 01 28; 137(4):456-458. Goodman AM, Kim MS, Prasad V. PMID: 33236046.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    60. Predicting Responses to Checkpoint Inhibitors in Lymphoma: Are We Up to the Standards of Solid Tumors? Clin Med Insights Oncol. 2020; 14:1179554920976366. Jeong AR, Ball ED, Goodman AM. PMID: 33447123; PMCID: PMC7780174.
      View in: PubMed   Mentions: 5  
    61. Cutaneous intralymphatic anaplastic lymphoma kinase-negative anaplastic large-cell lymphoma arising in a patient with multiple rounds of breast implants. J Cutan Pathol. 2021 May; 48(5):659-662. Wang HY, Thorson JA, Hinds BR, Swalchick W, Parker BA, Chong A, Wallace AM, Goodman AM. PMID: 33314229.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    62. Relationship between tumor mutational burden and maximum standardized uptake value in 2-[18F]FDG PET (positron emission tomography) scan in cancer patients. EJNMMI Res. 2020 Dec 09; 10(1):150. Haghighat Jahromi A, Barkauskas DA, Zabel M, Goodman AM, Frampton G, Nikanjam M, Hoh CK, Kurzrock R. PMID: 33296034; PMCID: PMC7726049.
      View in: PubMed   Mentions: 9  
    63. NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021. J Natl Compr Canc Netw. 2020 11 02; 18(11):1460-1467. Horwitz SM, Ansell S, Ai WZ, Barnes J, Barta SK, Clemens MW, Dogan A, Goodman AM, Goyal G, Guitart J, Halwani A, Haverkos BM, Hoppe RT, Jacobsen E, Jagadeesh D, Jones A, Kim YH, Mehta-Shah N, Olsen EA, Pro B, Rajguru SA, Rozati S, Said J, Shaver A, Shustov A, Sokol L, Torka P, Torres-Cabala C, Wilcox R, William BM, Zain J, Dwyer MA, Sundar H. PMID: 33152703.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    64. The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker. Cancer Cell. 2021 02 08; 39(2):154-173. Jardim DL, Goodman A, de Melo Gagliato D, Kurzrock R. PMID: 33125859; PMCID: PMC7878292.
      View in: PubMed   Mentions: 539     Fields:    Translation:HumansCells
    65. Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia in adults. Expert Opin Biol Ther. 2021 07; 21(7):849-862. Goldenson BH, Goodman AM, Ball ED. PMID: 32990476.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    66. Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy. Nat Commun. 2020 10 02; 11(1):4965. Kato S, Kim KH, Lim HJ, Boichard A, Nikanjam M, Weihe E, Kuo DJ, Eskander RN, Goodman A, Galanina N, Fanta PT, Schwab RB, Shatsky R, Plaxe SC, Sharabi A, Stites E, Adashek JJ, Okamura R, Lee S, Lippman SM, Sicklick JK, Kurzrock R. PMID: 33009371; PMCID: PMC7532150.
      View in: PubMed   Mentions: 129     Fields:    Translation:Humans
    67. Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease. Am J Hematol. 2020 12; 95(12):1553-1561. Fajgenbaum DC, Wu D, Goodman A, Wong R, Chadburn A, Nasta S, Srkalovic G, Mukherjee S, Leitch H, Jayanthan R, Ferrero S, Sato Y, Schey S, Dispenzieri A, Oksenhendler E, Zinzani PL, Lechowicz MJ, Hoffmann C, Pemmaraju N, Bagg A, Fossa A, Lim MS, van Rhee F, Castleman Disease Collaborative Network Scientific Advisory Board diagnostic criteria international . PMID: 32894785; PMCID: PMC9547644.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    68. High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naïve Patients with Diverse Cancers. Mol Cancer Ther. 2020 10; 19(10):2139-2145. Riviere P, Goodman AM, Okamura R, Barkauskas DA, Whitchurch TJ, Lee S, Khalid N, Collier R, Mareboina M, Frampton GM, Fabrizio D, Sharabi AB, Kato S, Kurzrock R. PMID: 32747422; PMCID: PMC7541603.
      View in: PubMed   Mentions: 43     Fields:    Translation:Humans
    69. Role of ultraviolet mutational signature versus tumor mutation burden in predicting response to immunotherapy. Mol Oncol. 2020 08; 14(8):1680-1694. Pham TV, Boichard A, Goodman A, Riviere P, Yeerna H, Tamayo P, Kurzrock R. PMID: 32530570; PMCID: PMC7400787.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    70. Afebrile Pneumonia in a Patient With Multicentric Castleman Disease on Siltuximab: Infection Without Fever on Anti-Interleukin-6 Therapy. Cureus. 2020 Jul 02; 12(7):e8967. Cohen PR, Nikanjam M, Kato S, Goodman AM, Kurzrock R. PMID: 32766009; PMCID: PMC7398726.
      View in: PubMed   Mentions: 1  
    71. Characterization of relapse patterns in patients with acute lymphoblastic leukemia treated with blinatumomab. J Oncol Pharm Pract. 2021 Jun; 27(4):821-826. Lau KM, Saunders IM, Goodman AM. PMID: 32605497.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    72. Tumor mutational burden is not predictive of cytotoxic chemotherapy response. Oncoimmunology. 2020 06 24; 9(1):1781997. Nikanjam M, Riviere P, Goodman A, Barkauskas DA, Frampton G, Kurzrock R. PMID: 32923144; PMCID: PMC7458654.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    73. Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era. Blood. 2020 05 28; 135(22):1929-1945. Goyal G, Heaney ML, Collin M, Cohen-Aubart F, Vaglio A, Durham BH, Hershkovitz-Rokah O, Girschikofsky M, Jacobsen ED, Toyama K, Goodman AM, Hendrie P, Cao XX, Estrada-Veras JI, Shpilberg O, Abdo A, Kurokawa M, Dagna L, McClain KL, Mazor RD, Picarsic J, Janku F, Go RS, Haroche J, Diamond EL. PMID: 32187362.
      View in: PubMed   Mentions: 130     Fields:    Translation:HumansCells
    74. MHC-I genotype and tumor mutational burden predict response to immunotherapy. Genome Med. 2020 05 19; 12(1):45. Goodman AM, Castro A, Pyke RM, Okamura R, Kato S, Riviere P, Frampton G, Sokol E, Zhang X, Ball ED, Carter H, Kurzrock R. PMID: 32430031; PMCID: PMC7236948.
      View in: PubMed   Mentions: 58     Fields:    Translation:Humans
    75. NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020. J Natl Compr Canc Netw. 2020 05; 18(5):522-536. Mehta-Shah N, Horwitz SM, Ansell S, Ai WZ, Barnes J, Barta SK, Clemens MW, Dogan A, Fisher K, Goodman AM, Goyal G, Guitart J, Halwani A, Haverkos BM, Hoppe RT, Jacobsen E, Jagadeesh D, Lunning MA, Mehta A, Olsen EA, Pro B, Rajguru SA, Shanbhag S, Shaver A, Shustov A, Sokol L, Torka P, Torres-Cabala C, Wilcox R, William BM, Zain J, Dwyer MA, Sundar H, Kim YH. PMID: 32380458.
      View in: PubMed   Mentions: 47     Fields:    Translation:Humans
    76. An IgA plasmacytoma: a rare and distinct form of plasmacytoma. Blood. 2020 04 23; 135(17):1505. Wang HY, Goodman AM. PMID: 32324872.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    77. Total Number of Alterations in Liquid Biopsies Is an Independent Predictor of Survival in Patients With Advanced Cancers. JCO Precis Oncol. 2020; 4. Vu P, Khagi Y, Riviere P, Goodman A, Kurzrock R. PMID: 32923910; PMCID: PMC7450932.
      View in: PubMed   Mentions: 16     Fields:    
    78. Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity. Oncoimmunology. 2020; 9(1):1708065. Kato S, Okamura R, Kumaki Y, Ikeda S, Nikanjam M, Eskander R, Goodman A, Lee S, Glenn ST, Dressman D, Papanicolau-Sengos A, Lenzo FL, Morrison C, Kurzrock R. PMID: 32117584; PMCID: PMC7028323.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansCells
    79. Prognostic implications of RAS alterations in diverse malignancies and impact of targeted therapies. Int J Cancer. 2020 06 15; 146(12):3450-3460. Kato S, Okamura R, Sicklick JK, Daniels GA, Hong DS, Goodman A, Weihe E, Lee S, Khalid N, Collier R, Mareboina M, Riviere P, Whitchurch TJ, Fanta PT, Lippman SM, Kurzrock R. PMID: 31782524; PMCID: PMC10200262.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    80. Real-World Toxicity Experience with BRAF/MEK Inhibitors in Patients with Erdheim-Chester Disease. Oncologist. 2020 02; 25(2):e386-e390. Saunders IM, Goodman AM, Kurzrock R. PMID: 32043767; PMCID: PMC7011668.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    81. Intensive Induction Therapy Compared With CHOP for Hepatosplenic T-cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2020 07; 20(7):431-437.e2. Klebaner D, Koura D, Tzachanis D, Ball ED, Horwitz S, Goodman AM. PMID: 32284297.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    82. Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy. Cancer Immunol Res. 2019 10; 7(10):1570-1573. Goodman AM, Sokol ES, Frampton GM, Lippman SM, Kurzrock R. PMID: 31405947; PMCID: PMC6774837.
      View in: PubMed   Mentions: 158     Fields:    Translation:HumansCells
    83. Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma. Oncotarget. 2019 Jun 18; 10(40):4018-4025. Ang C, Klempner SJ, Ali SM, Madison R, Ross JS, Severson EA, Fabrizio D, Goodman A, Kurzrock R, Suh J, Millis SZ. PMID: 31258846; PMCID: PMC6592287.
      View in: PubMed   Mentions: 91     Fields:    
    84. Safety and efficacy of direct oral anticoagulants for venous thromboembolism and stroke prophylaxis in patients with hematologic malignancies. J Oncol Pharm Pract. 2020 Mar; 26(2):351-360. Kim S, Namba J, Goodman AM, Nguyen T, Saunders IM. PMID: 31142232.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    85. Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis. Mol Cancer Ther. 2019 06; 18(6):1149-1157. Janku F, Diamond EL, Goodman AM, Raghavan VK, Barnes TG, Kato S, Abdel-Wahab O, Durham BH, Meric-Bernstam F, Kurzrock R. PMID: 31015311; PMCID: PMC6548628.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    86. Phenotypic and Genomic Determinants of Immunotherapy Response Associated with Squamousness. Cancer Immunol Res. 2019 06; 7(6):866-873. Goodman AM, Kato S, Chattopadhyay R, Okamura R, Saunders IM, Montesion M, Frampton GM, Miller VA, Daniels GA, Kurzrock R. PMID: 31003990; PMCID: PMC6548620.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    87. Schnitzler syndrome associated with MYD88 L265P mutation. JAAD Case Rep. 2019 Apr; 5(4):312-316. Goodman AM, Cohen PR, Li A, Hinds B, Kurzrock R. PMID: 30989098; PMCID: PMC6446129.
      View in: PubMed   Mentions: 4  
    88. Immune Escape of AML Cells after Transplantation. N Engl J Med. 2019 03 28; 380(13):1289. Goodman AM, Kurzrock R. PMID: 30917272.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    89. Pegaspargase-induced hypertriglyceridemia in a patient with acute lymphoblastic leukemia. J Oncol Pharm Pract. 2020 Jan; 26(1):193-199. Lau KM, Saunders IM, Goodman A. PMID: 30823860.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    90. Revisiting Epidermal Growth Factor Receptor (EGFR) Amplification as a Target for Anti-EGFR Therapy: Analysis of Cell-Free Circulating Tumor DNA in Patients With Advanced Malignancies. JCO Precis Oncol. 2019; 3. Kato S, Okamura R, Mareboina M, Lee S, Goodman A, Patel SP, Fanta PT, Schwab RB, Vu P, Raymond VM, Lanman RB, Sicklick JK, Lippman SM, Kurzrock R. PMID: 31058253; PMCID: PMC6497417.
      View in: PubMed   Mentions: 38     Fields:    
    91. APOBEC-related mutagenesis and neo-peptide hydrophobicity: implications for response to immunotherapy. Oncoimmunology. 2019; 8(3):1550341. Boichard A, Pham TV, Yeerna H, Goodman A, Tamayo P, Lippman S, Frampton GM, Tsigelny IF, Kurzrock R. PMID: 30723579; PMCID: PMC6350681.
      View in: PubMed   Mentions: 42     Fields:    
    92. Comprehensive Genomic Profiling Reveals Diverse but Actionable Molecular Portfolios across Hematologic Malignancies: Implications for Next Generation Clinical Trials. Cancers (Basel). 2018 Dec 21; 11(1). Galanina N, Bejar R, Choi M, Goodman A, Wieduwilt M, Mulroney C, Kim L, Yeerna H, Tamayo P, Vergilio JA, Mughal TI, Miller V, Jamieson C, Kurzrock R. PMID: 30583461; PMCID: PMC6356731.
      View in: PubMed   Mentions: 16  
    93. Genome-Wide Sequencing of Cell-Free DNA Identifies Copy-Number Alterations That Can Be Used for Monitoring Response to Immunotherapy in Cancer Patients. Mol Cancer Ther. 2019 02; 18(2):448-458. Jensen TJ, Goodman AM, Kato S, Ellison CK, Daniels GA, Kim L, Nakashe P, McCarthy E, Mazloom AR, McLennan G, Grosu DS, Ehrich M, Kurzrock R. PMID: 30523049.
      View in: PubMed   Mentions: 52     Fields:    Translation:HumansCells
    94. GNAS, GNAQ, and GNA11 alterations in patients with diverse cancers. Cancer. 2018 10 15; 124(20):4080-4089. Parish AJ, Nguyen V, Goodman AM, Murugesan K, Frampton GM, Kurzrock R. PMID: 30204251; PMCID: PMC6234097.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    95. Successful Treatment of HIV-Associated Kaposi Sarcoma with Immune Checkpoint Blockade. Cancer Immunol Res. 2018 10; 6(10):1129-1135. Galanina N, Goodman AM, Cohen PR, Frampton GM, Kurzrock R. PMID: 30194084; PMCID: PMC6248326.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    96. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood. 2018 11 15; 132(20):2115-2124. van Rhee F, Voorhees P, Dispenzieri A, Fosså A, Srkalovic G, Ide M, Munshi N, Schey S, Streetly M, Pierson SK, Partridge HL, Mukherjee S, Shilling D, Stone K, Greenway A, Ruth J, Lechowicz MJ, Chandrakasan S, Jayanthan R, Jaffe ES, Leitch H, Pemmaraju N, Chadburn A, Lim MS, Elenitoba-Johnson KS, Krymskaya V, Goodman A, Hoffmann C, Zinzani PL, Ferrero S, Terriou L, Sato Y, Simpson D, Wong R, Rossi JF, Nasta S, Yoshizaki K, Kurzrock R, Uldrick TS, Casper C, Oksenhendler E, Fajgenbaum DC. PMID: 30181172; PMCID: PMC6238190.
      View in: PubMed   Mentions: 183     Fields:    Translation:Humans
    97. Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors. JAMA Oncol. 2018 09 01; 4(9):1237-1244. Goodman AM, Piccioni D, Kato S, Boichard A, Wang HY, Frampton G, Lippman SM, Connelly C, Fabrizio D, Miller V, Sicklick JK, Kurzrock R. PMID: 29902298; PMCID: PMC6139049.
      View in: PubMed   Mentions: 148     Fields:    Translation:Humans
    98. Genomic landscape of advanced basal cell carcinoma: Implications for precision treatment with targeted and immune therapies. Oncoimmunology. 2018; 7(3):e1404217. Goodman AM, Kato S, Cohen PR, Boichard A, Frampton G, Miller V, Stephens PJ, Daniels GA, Kurzrock R. PMID: 29399405; PMCID: PMC5790366.
      View in: PubMed   Mentions: 32     Fields:    
    99. Erythrodermic Psoriasis in a Man with Monoclonal B-cell Lymphocytosis. Cureus. 2017 Dec 11; 9(12):e1936. Chen SX, Hinds BR, Goodman AM, Cohen PR. PMID: 29464143; PMCID: PMC5807020.
      View in: PubMed   Mentions: 1  
    100. Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor-Based Immunotherapy. Clin Cancer Res. 2017 Oct 01; 23(19):5729-5736. Khagi Y, Goodman AM, Daniels GA, Patel SP, Sacco AG, Randall JM, Bazhenova LA, Kurzrock R. PMID: 28972084; PMCID: PMC5678984.
      View in: PubMed   Mentions: 122     Fields:    Translation:Humans
    101. Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers. Mol Cancer Ther. 2017 11; 16(11):2598-2608. Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, Stephens PJ, Daniels GA, Kurzrock R. PMID: 28835386; PMCID: PMC5670009.
      View in: PubMed   Mentions: 1200     Fields:    Translation:HumansAnimalsCells
    102. Appearance of New Cutaneous Superficial Basal Cell Carcinomas during Successful Nivolumab Treatment of Refractory Metastatic Disease: Implications for Immunotherapy in Early Versus Late Disease. Int J Mol Sci. 2017 Jul 31; 18(8). Cohen PR, Kato S, Goodman AM, Ikeda S, Kurzrock R. PMID: 28788102; PMCID: PMC5578053.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    103. Next Generation Sequencing Reveals Potentially Actionable Alterations in the Majority of Patients with Lymphoid Malignancies. JCO Precis Oncol. 2017 06; 1. Goodman AM, Choi M, Wieduwilt M, Mulroney C, Costello C, Frampton G, Miller V, Kurzrock R. PMID: 28681041; PMCID: PMC5495179.
      View in: PubMed   Mentions: 15     Fields:    
    104. Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate. Clin Cancer Res. 2017 Aug 01; 23(15):4242-4250. Kato S, Goodman A, Walavalkar V, Barkauskas DA, Sharabi A, Kurzrock R. PMID: 28351930; PMCID: PMC5647162.
      View in: PubMed   Mentions: 468     Fields:    Translation:Humans
    105. What are the latest advancements in acute myeloid leukemia therapy? Future Oncol. 2017 Apr; 13(10):867-871. Goodman A, Ball ED. PMID: 28266249.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    106. A 60-Year-Old Man With Progressive Anemia While Receiving Checkpoint Blockade Therapy for Relapsed Myelofibrosis. Oncology (Williston Park). 2017 02 15; 31(2):122-4, 126-8. Goodman AM, Rust M, Costello C, Ball ED. PMID: 28205192.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    107. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas. Nat Rev Clin Oncol. 2017 04; 14(4):203-220. Goodman A, Patel SP, Kurzrock R. PMID: 27805626.
      View in: PubMed   Mentions: 239     Fields:    Translation:Humans
    108. Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy. NPJ Genom Med. 2016; 1. Ikeda S, Goodman AM, Cohen PR, Jensen TJ, Ellison CK, Frampton G, Miller V, Patel SP, Kurzrock R. PMID: 27942391; PMCID: PMC5142752.
      View in: PubMed   Mentions: 59  
    109. An 84-Year-Old Woman With an Indolent B-Cell Lymphoma. Oncology (Williston Park). 2016 08 15; 30(8):705-8, 710, 712. Goodman AM, Choi M, Wang L, Kurzrock R. PMID: 27535668.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    Aaron's Networks
    Concepts (270)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (59)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSD Profiles is managed by the UC San Diego Altman Clinical and Translational Research Institute (ACTRI).
    This site is running Profiles RNS version UCSF-v3.1.0-15-g9ae42700 on PROFILES-PWEB03. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California